Menu Close
Close
Contact

Clinical Trials in Neuromuscular Medicine

Southland Neuromuscular participates in ongoing and completed research involving Myasthenia Gravis, CIDP, inflammatory myopathy, Multifocal Motor Neuropathy, IVIG, and related neuromuscular therapies.

View Research Studies
Contact the Research Team

Neuromuscular Research Led by Dr. Samir P. Macwan

Dr. Samir P. Macwan is ABPN Board Certified in both Neurology and Neuromuscular Medicine. He has practiced Neuromuscular Medicine in the Greater Palm Springs area for 15 years and has been involved in research of Myasthenia Gravis, CIDP, Multifocal Motor Neuropathy, and Inflammatory Myositis. Dr. Macwan has served as Principal Investigator for ongoing and completed multicenter clinical trials examining treatment safety, treatment response, disease progression, quality of life, and long-term outcomes.

Current and Ongoing Neuromuscular Studies

Southland Neuromuscular’s research experience includes interventional and observational studies involving several complex neuromuscular conditions. Study availability and enrollment status can change, so patients should contact the research team for current information.

Principal Investigator: “ALXN-MG-501, Long-Term, Observational, Registry of Patients with Generalized Myasthenia Gravis Who Have Received Treatment with Complement C5 Inhibition Therapies”

Principal Investigator: A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older with Active Idiopathic Inflammatory Myopathy

Principal Investigator: A Phase 4, Open label, Prospective, Single Group, Multicenter Study to Evaluate the Clinical Outcomes of Egfartigimod PH20 SC in Adult Participants with New Onset Generalized Myasthenia Gravis

Principal Investigator: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients with Mild to Severe Generalized Myasthenia Gravis

Principal Investigator: A Global Real-World Study to Assess HyQvia Use and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Switching to HyQvia

Principal Investigator: A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Principal Investigator: A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of empasiprubart versus Intravenous Immunoglobulin (IVIg) in Adults with Multifocal Motor Neuropathy

Principal Investigator: A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Principal Investigator: A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults with Chronic Inflammatory Demyelinating Polyneuropathy

An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Principal Investigator: A Multicenter Prospective Longitudinal Study of Clinical Outcomes, Disease Course, Health-Related Quality of Life, and Health Care Resource Utilization in Adult Patients with Multifocal Motor Neuropathy

Principal Investigator: An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Principal Investigator: DDF, “IVIG in Dysimmune Inflammatory Neuropathy (DIN) with/without Diabetes Mellitus (DM)”

Principal Investigator: ADHERE: A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Principal Investigator: ADHERE+: Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Principal Investigator: MG 0017: An open-label study to evaluate the safety, tolerability, and efficacy of subcutaneous zilucoplan in participants with generalized myasthenia gravis who were previously receiving intravenous complement component 5 inhibitors

Study Coordinator (2004/05): “A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of Trexima (sumatriptan 85mg/naproxen sodium 500mg) tablets vs. placebo when administered during the mild phase of migraine”

University of Kansas Medical Center Research Day presentation (06/08): Case series of 11 patients of Primary Progressive Aphasia

University of Kansas Medical Center Research Day Presentation (06/09): Case series of 6 patients of myeloneuropathy due to copper deficiency

Efficacy of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy with or without diabetes: insights from a multicenter prospective comparative study. Macwan SP, Mahajan S, Novak P, Farhad K, Wong E, Brannagan TH, Masood S, Piracha F, Dalakas MC. Ther Adv Neurol Disord. 2025 Dec 21; 18:17562864251401496. Doi: 10.1177/1756864251401496. eCollection 2025. PMID: 41446323.

Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study.

Freimer M, Desai U, Govindarajan R, Kang MK, Khan S, Khatri B, Levine T, Macwan S, Shieh PB, Weiss MD, Bloemers J, Boroojerdi B, Delicha EM, Lavrov A, Singh P, Howard JF Jr.Ther Adv Neurol Disord. 2025 Jul 5;18:17562864251347283. doi: 10.1177/17562864251347283. eCollection 2025.

Sahai S, Macwan S. Atypical Facial Neuralgia. Journal of Practical Pain Management. Nov/Dec 2004; 4(6): 49-52.

Dang T, Macwan S, Dasanu C, Late-onset double seronegative myasthenia gravis syndrome and myasthenic crisis due to nivolumab use of Hodgkin’s lymphoma. Journal of Oncol Pharm Pract. 2020; 1177

The Mighty’s Lambert-Eaton Myasthenic Syndrome (LEMS) Condition Guide

The Mighty • October 1st, 2021

Medically reviewed by Dr. Samir Macwan, M.D.

Transforming healthcare for all

Current and Ongoing Neuromuscular Studies

Southland Neuromuscular’s research experience includes interventional and observational studies involving several complex neuromuscular conditions. Study availability and enrollment status can change, so patients should contact the research team for current information.

1

Generalized Myasthenia Gravis

ALXN-MG-501 Registry

A long-term observational registry following patients with generalized Myasthenia Gravis who have received treatment with complement C5 inhibition therapies.

New-Onset Generalized Myasthenia Gravis Study

A Phase 4, open-label, prospective, single-group multicenter study evaluating clinical outcomes with efgartigimod PH20 SC in adults with newly diagnosed generalized Myasthenia Gravis.

2
3
IMVT-1402 Myasthenia Gravis Study

A Phase 3, randomized, placebo-controlled, double-blind multicenter study assessing the efficacy and safety of IMVT-1402 in adults with mild to severe generalized Myasthenia Gravis.

Ask About Myasthenia Gravis Research

Idiopathic Inflammatory Myopathy

Efgartigimod PH20 SC Study

A Phase 2/3, randomized, double-blind, placebo-controlled multicenter study evaluating the efficacy, safety, tolerability, treatment response, and related outcomes of efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy.

The study includes inflammatory muscle conditions such as dermatomyositis, immune-mediated necrotizing myopathy, and certain other forms of active inflammatory myopathy.

Ask About Myositis Research
4
5

Chronic Inflammatory Demyelinating Polyneuropathy

HyQvia Real-World Outcomes Study

A global real-world study examining HyQvia use and clinical outcomes in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy who are switching to HyQvia.

IMVT-1402 CIDP Study

A Phase 2b, randomized, double-blind, placebo-controlled multicenter study evaluating IMVT-1402 treatment in adults with Chronic Inflammatory Demyelinating Polyneuropathy.

Ask About CIDP Research
6
7

Multifocal Motor Neuropathy

MMN Longitudinal Outcomes Study

A prospective multicenter study following adults with Multifocal Motor Neuropathy to examine clinical outcomes, disease progression, health-related quality of life, and healthcare resource use.

Ask About MMN Research

Neuromuscular Research Studies

Completed studies remain an important part of Southland Neuromuscular’s research experience and reflect Dr. Macwan’s work as Principal Investigator across multiple neuromuscular conditions.

DDF Study

Research examining IVIG in dysimmune inflammatory neuropathy in patients with or without diabetes mellitus.

ADHERE

A Phase 2 study investigating the efficacy, safety, and tolerability of efgartigimod PH20 SC in adults with Chronic Inflammatory Demyelinating Polyneuropathy.

ADHERE+

An open-label extension study examining the long-term safety, tolerability, and efficacy of efgartigimod PH20 SC in patients with CIDP.

MG 0017

An open-label study evaluating the safety, tolerability, and efficacy of subcutaneous zilucoplan in participants with generalized Myasthenia Gravis who had previously received intravenous complement component 5 inhibitors.

How to Ask About a Clinical Trial

Contacting the research team is the first step toward learning whether a study may be appropriate. It does not guarantee qualification or enrollment.

Tell the team about the diagnosed condition or study that interests you. A caregiver or referring physician may also contact the practice.

The research team may review age, diagnosis, symptoms, treatment history, current medications, previous therapies, and other study-specific requirements.

Patients who may qualify receive additional information about study visits, testing, treatment, possible risks, potential benefits, and alternatives before deciding whether to participate.

Clinical trial participation is voluntary. Potential participants are screened against the requirements of the individual study and may decide not to participate or may withdraw according to the study protocol.

Submit a Research Inquiry

Neuromuscular Clinical Trials FAQs

A neuromuscular clinical trial is a research study involving people with nerve, muscle, or neuromuscular junction conditions. A study may evaluate an investigational treatment, an approved therapy used in a specific setting, long-term safety, disease progression, quality of life, or treatment outcomes.

Each study has its own eligibility requirements. Qualification may depend on diagnosis, age, symptom severity, test results, current medications, previous treatments, other medical conditions, and study location. The research team must review this information before determining whether further screening is appropriate.

No. Contacting the research team only begins the inquiry and screening process. A person may appear eligible during an initial conversation but not meet all study requirements after medical records, testing, or other criteria are reviewed. Enrollment also depends on whether the study is still accepting participants.

Do not stop or change medication unless instructed by the treating physician or research team. Some studies require participants to remain on stable treatment, while others have restrictions involving particular medications. These requirements should be explained during screening and informed consent before participation begins.

Ask About Current Neuromuscular Research

Call Southland Neuromuscular